Home > Publications database > Higher vitamin B6 status is associated with improved survival among patients with stage I-III colorectal cancer. > print

001     180076
005     20240229145604.0
024 7 _ |a 10.1093/ajcn/nqac090
|2 doi
024 7 _ |a pmid:35394006
|2 pmid
024 7 _ |a 0002-9165
|2 ISSN
024 7 _ |a 0095-9871
|2 ISSN
024 7 _ |a 1938-3207
|2 ISSN
024 7 _ |a 1938-3215
|2 ISSN
024 7 _ |a altmetric:126229413
|2 altmetric
037 _ _ |a DKFZ-2022-01075
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Holowatyj, Andreana N
|b 0
245 _ _ |a Higher vitamin B6 status is associated with improved survival among patients with stage I-III colorectal cancer.
260 _ _ |a Oxford
|c 2022
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1662120058_21383
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Aug 4;116(2):303-313
520 _ _ |a Folate-mediated one-carbon metabolism requires several nutrients, including vitamin B6. Circulating levels of biomarkers indicating high vitamin B6 status are associated with a reduced risk of colorectal cancer (CRC). However, little is known about the effect of B6 status in relation to clinical outcomes in CRC patients.We investigated survival outcomes in relation to vitamin B6 status in prospectively followed CRC patients.A total of 2031 patients with stage I-III CRC participated in six prospective patient cohorts in the international FOCUS Consortium. Preoperative blood samples were used to measure vitamin B6 status by the direct marker pyridoxal 5'-phosphate, PLP, as well as functional marker the HK-ratio (3'-hydroxykynurenine: [kynurenic acid + xanthurenic acid + 3'-hydroxy anthranilic acid + anthranilic acid]). Using Cox proportional hazards regression, we examined associations of vitamin B6 status with overall survival (OS), disease-free survival (DFS), and risk of recurrence, adjusted for patient age, sex, circulating creatinine levels, tumor site, stage, and cohort.After a median follow-up of 3.2 years for OS, higher preoperative vitamin B6 status as assessed by PLP and the functional marker HKr was associated with 16-32% higher all-cause and disease-free survival, although there was no significant association with disease recurrence (doubling in PLP concentration: hazard ratio, HROS, 0.68; 95% CI, 0.59,0.79; HRDFS, 0.84; 95% CI, 0.75,0.94; HRRecurrence, 0.96; 95% CI, 0.84,1.09; HKr: HROS, 2.04; 95% CI, 1.67,2.49; HRDFS, 1.56; 95% CI, 1.31,1.85; HRRecurrence, 1.21; 95% CI, 0.96,1.52). The association of PLP with improved OS was consistent across colorectal tumor site (right-sided colon: HROS, 0.75; 95% CI, 0.59,0.96; left-sided colon: HROS, 0.71; 95% CI, 0.55,0.92; rectosigmoid junction and rectum: HROS, 0.61; 95% CI, 0.47,0.78).Higher preoperative vitamin B6 status is associated with improved OS among stage I-III CRC patients.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HKr
|2 Other
650 _ 7 |a PAR
|2 Other
650 _ 7 |a PLP
|2 Other
650 _ 7 |a cancer
|2 Other
650 _ 7 |a colon cancer
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a mortality
|2 Other
650 _ 7 |a one-carbon metabolism
|2 Other
650 _ 7 |a rectal cancer
|2 Other
650 _ 7 |a recurrence
|2 Other
650 _ 7 |a survival
|2 Other
650 _ 7 |a survivorship
|2 Other
650 _ 7 |a vitamin b6
|2 Other
650 _ 7 |a vitamins
|2 Other
700 1 _ |a Ose, Jennifer
|b 1
700 1 _ |a Gigic, Biljana
|b 2
700 1 _ |a Lin, Tengda
|b 3
700 1 _ |a Ulvik, Arve
|b 4
700 1 _ |a Geijsen, Anne J M R
|b 5
700 1 _ |a Brezina, Stefanie
|b 6
700 1 _ |a Kiblawi, Rama
|b 7
700 1 _ |a van Roekel, Eline H
|b 8
700 1 _ |a Baierl, Andreas
|b 9
700 1 _ |a Böhm, Jürgen
|b 10
700 1 _ |a Bours, Martijn J L
|b 11
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 12
|u dkfz
700 1 _ |a Breukink, Stéphanie O
|b 13
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 14
|u dkfz
700 1 _ |a de Wilt, Johannes H W
|b 15
700 1 _ |a Grady, William M
|b 16
700 1 _ |a Grünberger, Thomas
|b 17
700 1 _ |a Gumpenberger, Tanja
|b 18
700 1 _ |a Herpel, Esther
|b 19
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 20
|u dkfz
700 1 _ |a Keulen, Eric T P
|b 21
700 1 _ |a Kok, Dieuwertje E
|b 22
700 1 _ |a Koole, Janna L
|b 23
700 1 _ |a Kosma, Katharina
|b 24
700 1 _ |a Kouwenhoven, Ewout A
|b 25
700 1 _ |a Kvalheim, Gry
|b 26
700 1 _ |a Li, Christopher I
|b 27
700 1 _ |a Schirmacher, Peter
|b 28
700 1 _ |a Schrotz-King, Petra
|0 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
|b 29
|u dkfz
700 1 _ |a Singer, Marie C
|b 30
700 1 _ |a van Duijnhoven, Fränzel J B
|b 31
700 1 _ |a van Halteren, Henk K
|b 32
700 1 _ |a Vickers, Kathy
|b 33
700 1 _ |a Vogelaar, F Jeroen
|b 34
700 1 _ |a Warby, Christy A
|b 35
700 1 _ |a Wesselink, Evertine
|b 36
700 1 _ |a Ueland, Per M
|b 37
700 1 _ |a Ulrich, Alexis B
|b 38
700 1 _ |a Schneider, Martin
|b 39
700 1 _ |a Habermann, Nina
|b 40
700 1 _ |a Kampman, Ellen
|b 41
700 1 _ |a Weijenberg, Matty P
|b 42
700 1 _ |a Gsur, Andrea
|b 43
700 1 _ |a Ulrich, Cornelia M
|b 44
773 _ _ |a 10.1093/ajcn/nqac090
|g p. nqac090
|0 PERI:(DE-600)1496439-9
|n 2
|p 303-313
|t The American journal of clinical nutrition
|v 116
|y 2022
|x 0002-9165
909 C O |p VDB
|o oai:inrepo02.dkfz.de:180076
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-17
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21